JAZZ vs USPH · P/E 1988, rev $4.07B vs P/E 34, rev $671.3M
Jazz Pharmaceuticals PLC (JAZZ) versus US Physicalrapy Inc (USPH) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
US Physicalrapy Inc (USPH) is a medical care facilities company listed on US.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported USPH revenue for 2024-12-31 was $671.3M. Net income was $45.6M. Revenue was up 11.0% from 2023-12-31 to 2024-12-31. USPH currently screens at market cap $1.13B and trailing P/E 34.2.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. USPH currently screens at market cap $1.13B and trailing P/E 34.2.
Not investment advice. Open the JAZZ and USPH stock pages for the full models.
Not investment advice.